Please assess the completion status of the following clinical trial:

Trial Title: Safety of Intravenous Thrombolytics in Stroke on Awakening

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater or equal to 18 years, and lower or equal to 80 years.~* Signs and symptoms of acute ischemic stroke.~* Symptoms present upon awakening.~* Arriving to the Emergency Department within 4.5 hours of awakening. Treatment with IV tPA must be initiated prior to 4.5hours from waking up.~* NIHSS \>3~* A non-contrast head CT without hemorrhage and without hypodensity more than 1/3 of the middle cerebral artery (MCA) territory; or MRI demonstrating no hemorrhage, and with a diffusion-weighted imaging (DWI) lesion no greater than 70 mL and FLAIR without a well defined hyperintense lesion that is more than 1/3 of the MCA territory.~* Pre-morbid modified Rankin score of 0 or 1.~Exclusion Criteria:~* Rapidly improving deficit to an NIHSS less than 3.~* Sustained systolic blood pressure greater than 185 mmHg or diastolic blood pressure greater than 110 mmHg despite treatment.~* Glucose less than 50 mg/dL.~* Stroke or head trauma within last 3 months.~* History of intracranial hemorrhage. Symptoms of subarachnoid hemorrhage.~* Major surgery within 14 days.~* Gastrointestinal (GI)/Genito-urinary (GU) hemorrhage within 21 days.~* International normalized ratio (INR) \> 1.7.~* Heparin within 48 hours with an elevated activated partial thromboplastin time (aPTT).~* Platelet count less than 100,000.~* Presumed septic embolus or suspicion of bacterial endocarditis.~* Suspicion of aortic dissection.~* Use of anticoagulants such as dabigatran, rivaroxaban, apixaban, enoxaparin.~* Pregnant or lactating women.~* Known allergy or sensitivity to tPA.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- IV tPA (Type: EXPERIMENTAL): Treatment will be initiated within 4.5 hours of awakening, for patients who meet inclusion criteria

Based on this trial design, predict the completion outcome and termination type (if applicable).